lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-27. Numbers and descriptions here follow the published literature rather than marketing material.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | Reversed-phase HPLC with UV detection | Separates target peptide from truncated and oxidised forms |
| Identity confirmation | LC-MS or ESI-MS | Compares observed and calculated molecular ion |
| Primary degradation route | Methionine oxidation | Forms the sulfoxide; monitored as an early-eluting peak |
| Short-term storage | 2 to 8 degrees Celsius | Applies to working vials and reconstituted portions |
| Common synonyms | ACTH(4–10) analogue, MEHFPGP | Descriptive names used in laboratory catalogues |
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
=== Second allegation of domestic abuse === About six months after the ATP declined to take action against Zverev, in July 2023, allegations from a second woman became public through a court filing. The public prosecution office requested a penalty order against Zverev in a Berlin criminal court over alleged bodily harm against Brenda Patea, Zverev's ex-girlfriend and the mother of his daughter. On 2 October 2023, the court issued a summary penalty order against Zverev, which included a fine of €450,000. In Germany, summary orders can be issued, typically without a prior hearing, when a judge considers the evidence sufficient to support the accusation and a trial is not deemed necessary. Zverev lodged an objection against the order, which under German law resulted in a public trial. Patea spoke publicly for the first time about the alleged abuse on 1 November 2023 in an interview with the Süddeutsche Zeitung. She said that during a dispute in May 2020, Zverev pushed her into a wall and choked her. In January 2024, Zverev was appointed to serve on the ATP Players Advisory Council. The ATP has been criticized for allowing him to serve on the council while the domestic abuse charge is pending in a criminal court. Also in January 2024, Zverev was featured on the second season of the Netflix series Break Point in an episode focused on his comeback from injury. Netflix was criticized for ignoring both allegations of domestic abuse. One columnist argued that "Break Point promised to take viewers behind the curtain of professional tennis and reveal the personalities behind it.
You see, we were having negotiations with these lunatics, and it was my opinion that they [the Iranians] were going to attack first." On April 2, US president Trump stated he does not "care" about Iran's stock of highly enriched uranium (HEU) as it is underground, contradicting a key rationale he brought up when starting the war. In fact, Iran's HEU stock is now assessed as a more risky scenario than before the war began, as it would leave Iran significantly closer to the capability of making nuclear bombs than the proposed settlement being negotiated in Geneva two days before the war began. Iran's development of HEU stockpile itself is the consequence of Trump's decision in 2018 to withdraw from a multilateral nuclear deal. Another reason given by the Trump administration for initiating the war was the desire to seize Iran's oil and gas resources. According to the political scientist Vali Nasr, Trump aspired to become the American president who finally resolved the Iran problem.
=== 4. Periodontal ligament === The periodontal ligament is the principal connective tissue structure anchoring the tooth to the surrounding alveolar bone. During clinical attachment loss, the collagen fiber bundles are progressively destroyed. The most apical extent of the remaining periodontal ligament shifts downward along the root surface, corresponding directly to the measured level of clinical attachment loss.
Phillips acquired Experimental and Applied Sciences (EAS) from founders Anthony Almada and Ed Byrd in 1996. He promoted the company's products through heavy editorial-style advertisements in MM2K and, led by flagship products like Myoplex (a meal replacement powder), the creatine supplement Phosphagen, and HMB, he eventually rose to the forefront of the nutritional supplement industry, where he remained for more than five years. By 1995 Phillips was a multi-millionaire, and was well known in celebrity and sports circles. Athletes like José Canseco would contact Phillips for advice on steroids, and he also consulted with celebrities such as Jerry Seinfeld, John Elway, Sylvester Stallone and Demi Moore. In 1999, Phillips sold his majority interest in EAS (though he remained on the Board of Directors for a number of years afterward) to North Castle Partners for $160 million. Phillips retained about a third of the company, which he sold in 2004 and is no longer involved with EAS.
Sources: en.wikipedia.org
== History == In 1976, Gustilo and Anderson refined the early classification system proposed by Veliskasis in 1959. An early study conducted by Gustilo in 1976 showed that primary closures with prophylactic antibiotics of Type I and type II fractures reduced the risk of infection by 84.4%. Meanwhile, early internal fixation and primary closure of the wound in Type III fractures have a greater risk of getting osteomyelitis. However, Type III fractures occur in 60% of all the open fracture cases. Infection of the Type III fractures is observed in 10% to 50% of the time. Therefore, in 1984, Gustilo subclassified Type III fractures into A, B, and C with the aim of guiding the treatment of open fractures, communication and research, and to predict outcomes. Based on the results of the previous studies, Gustilo initially recommended therapeutic irrigation and surgical debridement for all fractures with primary closure for Type I and II fractures; secondary closure without internal fixation for Type III fractures. However, soon after that, he recommended internal fixation devices for Type III fractures.
=== Pseudomorphic replication === Pseudomorphic mineral replacement events occur whenever a mineral phase comes into contact with a fluid with which it is out of equilibrium. Re-equilibration will tend to take place to reduce the free energy and transform the initial phase into a more thermodynamically stable phase, involving dissolution and reprecipitation subprocesses. Inspired by such geological processes, MOF thin films can be grown through the combination of atomic layer deposition (ALD) of aluminum oxide onto a suitable substrate (e.g. FTO) and subsequent solvothermal microwave synthesis. The aluminum oxide layer serves both as an architecture-directing agent and as a metal source for the backbone of the MOF structure. The construction of the porous 3D metal-organic framework takes place during the microwave synthesis, when the atomic layer deposited substrate is exposed to a solution of the requisite linker in a DMF/H2O 3:1 mixture (v/v) at elevated temperature. Analogous, Kornienko and coworkers described in 2015 the synthesis of a cobalt-porphyrin MOF (Al2(OH)2tcpp-Co; H2tcpp-=4,4′,4″,4‴-(porphyrin-5,10,15,20-tetrayl)tetrabenzoate), the first MOF catalyst constructed for the electrocatalytic conversion of aqueous CO2 to CO.
=== Biodegradation === Because of the volume of surfactants released into the environment, for example laundry detergents in waters, their biodegradation is of great interest. Attracting much attention is the non-biodegradability and extreme persistence of fluorosurfactant, e.g. perfluorooctanoic acid (PFOA). Strategies to enhance degradation include ozone treatment and biodegradation. Two major surfactants, linear alkylbenzene sulfonates (LAS) and the alkyl phenol ethoxylates (APE) break down under aerobic conditions found in sewage treatment plants and in soil to nonylphenol, which is thought to be an endocrine disruptor. Interest in biodegradable surfactants has led to much interest in "biosurfactants" such as those derived from amino acids. Biobased surfactants can offer improved biodegradation. However, whether surfactants damage the cells of fish or cause foam mountains on bodies of water depends primarily on their chemical structure and not on whether the carbon originally used came from fossil sources, carbon dioxide or biomass.
Sources: en.wikipedia.org
General elections were held in Thailand on 8 February 2026 in order to determine the composition of the House of Representatives. A referendum was also held on the same day so as to determine whether the 2017 constitution should be replaced with a new one. After the 2023 general election, three coalition governments were formed by the resulting parliament. After an initial attempt by the progressive Move Forward Party was blocked by the Senate, the Pheu Thai Party split off to form governments with conservative and pro-military parties, first under Srettha Thavisin and later under Paetongtarn Shinawatra. Both governments collapsed, with Srettha removed by a court ruling in 2024 and Paetongtarn dismissed by the Constitutional Court in 2025. In September 2025, an agreement was made between the People's Party and Bhumjaithai Party to support Anutin Charnvirakul as prime minister, with a requirement for Anutin to dissolve the House within 4 months after the presentation of the government's policy platform. The House was dissolved on 12 December 2025, with a snap election being required within 60 days. The election was scheduled for 8 February 2026, the latest possible date. The election resulted in the Bhumjaithai Party winning the most seats in the House of Representatives, with 192. The People's Party, led by Natthaphong Ruengpanyawut, followed in second place with 120 seats. Pheu Thai, led by Yodchanan Wongsawat, came in third with 74 seats. There was a drop in turnout, which was 4.22 percentage points down compared to the last election.
== Function == The protein encoded by this gene contains a classical signature of the insulin superfamily and is significantly similar to relaxin and relaxin-like factor. This gene is preferentially expressed in testis. Its expression in testis is restricted to interstitial cells surrounding seminiferous tubules, which suggests a role in sperm development and fertilization.
Pandey has the Human Proteome Organization(HUPO)'s Discovery in Proteomic Sciences Award. The Wellcome Trust/DBT India Alliance named him a Margdarshi Fellow, and he established a Center for Molecular Medicine at NIMHANS in Bangalore as a result. He is an Associate Editor of Clinical Proteomics and a member of the Editorial Boards of Molecular and Cellular Proteomics, Proteomics, and the Journal of Clinical Investigation. He has received the Howard Temin Award from the National Cancer Institute, the Experimental Pathologist-In-Training Award from the American Society for Investigative Pathology, and the Sidney Kimmel Scholar Award from the Sidney Kimmel Foundation for Cancer Research. The United States Department of Defense also bestowed upon him the Era of Hope Scholar Award.
Sources: en.wikipedia.org
Dry powder is usually kept at about -20 degrees Celsius for long-term storage and at 2 to 8 degrees Celsius for short working periods. Containers should stay sealed and protected from light and moisture to limit degradation.
Oxidation of the methionine residue to the sulfoxide is a frequently reported change, and it usually appears as an earlier-eluting peak in reversed-phase chromatography. Backbone hydrolysis products can also accumulate in aqueous solution.
Liquid chromatography coupled with mass spectrometry is the usual approach, because the observed molecular ion can be compared with a calculated mass of about 813.9 Da. Retention time alone does not establish identity.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.